1CM Past Earnings Performance
Past criteria checks 0/6
1CM has been growing earnings at an average annual rate of 55%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 85% per year.
Key information
55.0%
Earnings growth rate
57.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 85.0% |
| Return on equity | -2.1% |
| Net Margin | -1.1% |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
Recent updates
1CM Inc. (CSE:EPIC) Might Not Be As Mispriced As It Looks After Plunging 30%
Sep 29
1CM Inc. (CSE:EPIC) Stock's 32% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Not Many Are Piling Into 1CM Inc. (CSE:EPIC) Stock Yet As It Plummets 32%
Jun 16Why We're Not Concerned Yet About 1CM Inc.'s (CSE:EPIC) 33% Share Price Plunge
Apr 27What You Can Learn From 1CM Inc.'s (CSE:EPIC) P/S
Feb 07Investors Appear Satisfied With 1CM Inc.'s (CSE:EPIC) Prospects
Jun 27Revenue & Expenses Breakdown
How 1CM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 52 | -1 | 8 | 0 |
| 29 Feb 24 | 46 | -1 | 7 | 0 |
| 30 Nov 23 | 40 | -2 | 7 | 0 |
| 31 Aug 23 | 35 | -1 | 6 | 0 |
| 31 May 23 | 24 | -2 | 7 | 0 |
| 28 Feb 23 | 15 | -3 | 6 | 0 |
| 30 Nov 22 | 8 | -3 | 4 | 0 |
| 31 Aug 22 | 1 | -5 | 3 | 0 |
| 31 May 22 | 1 | -5 | 4 | 0 |
| 28 Feb 22 | 1 | -5 | 5 | 0 |
| 30 Nov 21 | 1 | -5 | 4 | 0 |
| 31 Aug 21 | 0 | -5 | 4 | 0 |
| 31 May 21 | 0 | -4 | 2 | 0 |
| 28 Feb 21 | 0 | -3 | 1 | 0 |
| 30 Nov 20 | 0 | -3 | 1 | 0 |
| 31 Aug 20 | 0 | -3 | 1 | 0 |
| 31 May 20 | 0 | -28 | 1 | 0 |
| 29 Feb 20 | 0 | -28 | 1 | 0 |
| 30 Nov 19 | 0 | -28 | 1 | 0 |
| 31 Aug 19 | 0 | -29 | 1 | 0 |
| 31 May 19 | 0 | -7 | 5 | 0 |
| 28 Feb 19 | 0 | -8 | 6 | 0 |
| 30 Nov 18 | 0 | -7 | 6 | 0 |
| 31 Aug 18 | 0 | -6 | 6 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | 0 | 0 | 0 |
| 30 Nov 17 | 0 | 0 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | -1 | 0 | 0 |
| 29 Feb 16 | 0 | -1 | 0 | 0 |
| 30 Nov 15 | 0 | -1 | 0 | 0 |
| 31 Aug 15 | 0 | -1 | 0 | 0 |
| 31 May 15 | 0 | -1 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
| 30 Nov 14 | 0 | -2 | 0 | 0 |
Quality Earnings: EPIC is currently unprofitable.
Growing Profit Margin: EPIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPIC is unprofitable, but has reduced losses over the past 5 years at a rate of 55% per year.
Accelerating Growth: Unable to compare EPIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: EPIC has a negative Return on Equity (-2.06%), as it is currently unprofitable.